{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:01:03Z","timestamp":1777982463700,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":89,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789811915918","type":"print"},{"value":"9789811915925","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-981-19-1592-5_11","type":"book-chapter","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:03:09Z","timestamp":1652662989000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HDL Mimetic Peptides"],"prefix":"10.1007","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiewen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"11_CR1","first-page":"25","volume":"67","author":"E Jokinen","year":"2015","unstructured":"Jokinen E (2015) Obesity and cardiovascular disease. Minerva Pediatr 67:25\u201332","journal-title":"Minerva Pediatr"},{"issue":"6","key":"11_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/biom10060829","volume":"10","author":"A Rivas-Urbina","year":"2020","unstructured":"Rivas-Urbina A et al (2020) Subcutaneous Administration of Apolipoprotein J-derived mimetic peptide d-[113-122]apoJ improves LDL and HDL function and prevents atherosclerosis in LDLR-KO mice. Biomol Ther 10(6):829. https:\/\/doi.org\/10.3390\/biom10060829","journal-title":"Biomol Ther"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS et al (2016) Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 13:48\u201360. https:\/\/doi.org\/10.1038\/nrcardio.2015.124","journal-title":"Nat Rev Cardiol"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/978-3-319-09665-0_21","volume":"224","author":"RM Stoekenbroek","year":"2015","unstructured":"Stoekenbroek RM, Stroes ES, Hovingh GK (2015) ApoA-I mimetics. Handb Exp Pharmacol 224:631\u2013648. https:\/\/doi.org\/10.1007\/978-3-319-09665-0_21","journal-title":"Handb Exp Pharmacol"},{"key":"11_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b92","volume":"338","author":"M Briel","year":"2009","unstructured":"Briel M et al (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92. https:\/\/doi.org\/10.1136\/bmj.b92","journal-title":"BMJ"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572\u2013580. https:\/\/doi.org\/10.1016\/S0140-6736(12)60312-2","journal-title":"Lancet"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2008.03.016","volume":"51","author":"EM deGoma","year":"2008","unstructured":"deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51:2199\u20132211. https:\/\/doi.org\/10.1016\/j.jacc.2008.03.016","journal-title":"J Am Coll Cardiol"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1194\/jlr.R051367","volume":"55","author":"CR White","year":"2014","unstructured":"White CR, Garber DW, Anantharamaiah GM (2014) Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res 55:2007\u20132021. https:\/\/doi.org\/10.1194\/jlr.R051367","journal-title":"J Lipid Res"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1194\/jlr.M049262","volume":"55","author":"Y Zhao","year":"2014","unstructured":"Zhao Y et al (2014) In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res 55:2053\u20132063. https:\/\/doi.org\/10.1194\/jlr.M049262","journal-title":"J Lipid Res"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3949\/ccjm.79a.11166","volume":"79","author":"SJ Nicholls","year":"2012","unstructured":"Nicholls SJ (2012) Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med 79:38\u201343. https:\/\/doi.org\/10.3949\/ccjm.79a.11166","journal-title":"Cleve Clin J Med"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/bjp.2008.248","volume":"154","author":"TR Joy","year":"2008","unstructured":"Joy TR, Hegele RA (2008) The failure of torcetrapib: what have we learned? Br J Pharmacol 154:1379\u20131381. https:\/\/doi.org\/10.1038\/bjp.2008.248","journal-title":"Br J Pharmacol"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1253\/circj.CJ-15-0960","volume":"79","author":"Y Uehara","year":"2015","unstructured":"Uehara Y, Chiesa G, Saku K (2015) High-density lipoprotein-targeted therapy and apolipoprotein A-I mimetic peptides. Circ J 79:2523\u20132528. https:\/\/doi.org\/10.1253\/circj.CJ-15-0960","journal-title":"Circ J"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/BJ20150832","volume":"472","author":"D Sviridov","year":"2015","unstructured":"Sviridov D, Remaley AT (2015) High-density lipoprotein mimetics: promises and challenges. Biochem J 472:249\u2013259. https:\/\/doi.org\/10.1042\/BJ20150832","journal-title":"Biochem J"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fphar.2019.00536","volume":"10","author":"GS Getz","year":"2019","unstructured":"Getz GS, Reardon CA (2019) Apoproteins E, A-I, and SAA in macrophage pathobiology related to atherogenesis. Front Pharmacol 10:536. https:\/\/doi.org\/10.3389\/fphar.2019.00536","journal-title":"Front Pharmacol"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","volume":"91","author":"AS Plump","year":"1994","unstructured":"Plump AS, Scott CJ, Breslow JL (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91:9607\u20139611. https:\/\/doi.org\/10.1073\/pnas.91.20.9607","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE et al (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292\u20132300. https:\/\/doi.org\/10.1001\/jama.290.17.2292","journal-title":"JAMA"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/biof.1205","volume":"41","author":"R Namiri-Kalantari","year":"2015","unstructured":"Namiri-Kalantari R et al (2015) The dual nature of HDL: anti-inflammatory and pro-inflammatory. Biofactors 41:153\u2013159. https:\/\/doi.org\/10.1002\/biof.1205","journal-title":"Biofactors"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-07320-0_8","volume":"824","author":"L Vakili","year":"2014","unstructured":"Vakili L et al (2014) Systemic inflammation, intestine, and paraoxonase-1. Adv Exp Med Biol 824:83\u201388. https:\/\/doi.org\/10.1007\/978-3-319-07320-0_8","journal-title":"Adv Exp Med Biol"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1749-6632.1980.tb21313.x","volume":"348","author":"D Fukushima","year":"1980","unstructured":"Fukushima D et al (1980) Rational design of synthetic models for lipoproteins. Ann N Y Acad Sci 348:365\u2013377. https:\/\/doi.org\/10.1111\/j.1749-6632.1980.tb21313.x","journal-title":"Ann N Y Acad Sci"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1073\/pnas.80.4.1137","volume":"80","author":"ET Kaiser","year":"1983","unstructured":"Kaiser ET, Kezdy FJ (1983) Secondary structures of proteins and peptides in amphiphilic environments. (A review). Proc Natl Acad Sci U S A 80:1137\u20131143. https:\/\/doi.org\/10.1073\/pnas.80.4.1137","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"11464","DOI":"10.1016\/S0021-9258(19)70314-7","volume":"255","author":"P Kanellis","year":"1980","unstructured":"Kanellis P et al (1980) Studies of synthetic peptide analogs of the amphipathic helix. Effect of charged amino acid residue topography on lipid affinity. J Biol Chem 255:11464\u201311472","journal-title":"J Biol Chem"},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"10248","DOI":"10.1016\/S0021-9258(17)39238-4","volume":"260","author":"GM Anantharamaiah","year":"1985","unstructured":"Anantharamaiah GM et al (1985) Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 260:10248\u201310255","journal-title":"J Biol Chem"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.drudis.2016.08.010","volume":"22","author":"YN Cao","year":"2017","unstructured":"Cao YN et al (2017) Recombinant high-density lipoproteins and their use in cardiovascular diseases. Drug Discov Today 22:180\u2013185. https:\/\/doi.org\/10.1016\/j.drudis.2016.08.010","journal-title":"Drug Discov Today"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/prot.340150403","volume":"15","author":"YV Venkatachalapathi","year":"1993","unstructured":"Venkatachalapathi YV et al (1993) Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins 15:349\u2013359. https:\/\/doi.org\/10.1002\/prot.340150403","journal-title":"Proteins"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/s0022-2275(20)31599-6","volume":"42","author":"G Datta","year":"2001","unstructured":"Datta G et al (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 42:1096\u20131104. https:\/\/doi.org\/10.1016\/s0022-2275(20)31599-6","journal-title":"J Lipid Res"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.redox.2017.11.027","volume":"15","author":"D He","year":"2018","unstructured":"He D et al (2018) Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biol 15:228\u2013242. https:\/\/doi.org\/10.1016\/j.redox.2017.11.027","journal-title":"Redox Biol"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11883-010-0097-4","volume":"12","author":"GS Getz","year":"2010","unstructured":"Getz GS, Wool GD, Reardon CA (2010) Biological properties of apolipoprotein a-I mimetic peptides. Curr Atheroscler Rep 12:96\u2013104. https:\/\/doi.org\/10.1007\/s11883-010-0097-4","journal-title":"Curr Atheroscler Rep"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1096\/fj.10-165670","volume":"25","author":"GD Wool","year":"2011","unstructured":"Wool GD et al (2011) 4F peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J 25:290\u2013300. https:\/\/doi.org\/10.1096\/fj.10-165670","journal-title":"FASEB J"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/hc0302.103711","volume":"105","author":"M Navab","year":"2002","unstructured":"Navab M et al (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105:290\u2013292. https:\/\/doi.org\/10.1161\/hc0302.103711","journal-title":"Circulation"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.2337\/db10-0844","volume":"59","author":"C Morgantini","year":"2010","unstructured":"Morgantini C et al (2010) Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 59:3223\u20133228. https:\/\/doi.org\/10.2337\/db10-0844","journal-title":"Diabetes"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11883-015-0539-0","volume":"17","author":"JS Millar","year":"2015","unstructured":"Millar JS, Cuchel M (2015) ApoA-I-directed therapies for the Management of Atherosclerosis. Curr Atheroscler Rep 17:60. https:\/\/doi.org\/10.1007\/s11883-015-0539-0","journal-title":"Curr Atheroscler Rep"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/187231210791698438","volume":"4","author":"S Imaizumi","year":"2010","unstructured":"Imaizumi S et al (2010) L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 4:139\u2013148. https:\/\/doi.org\/10.2174\/187231210791698438","journal-title":"Drug Metab Lett"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","volume":"109","author":"M Navab","year":"2004","unstructured":"Navab M et al (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215\u20133220. https:\/\/doi.org\/10.1161\/01.CIR.0000134275.90823.87","journal-title":"Circulation"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"R529","DOI":"10.1152\/ajpregu.00185.2019","volume":"318","author":"RS Moreira","year":"2020","unstructured":"Moreira RS et al (2020) Synthetic apolipoprotein A-I mimetic peptide 4F protects hearts and kidneys after myocardial infarction. Am J Physiol Regul Integr Comp Physiol 318:R529\u2013R544. https:\/\/doi.org\/10.1152\/ajpregu.00185.2019","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"C1538","DOI":"10.1152\/ajpcell.00467.2009","volume":"298","author":"LE Smythies","year":"2010","unstructured":"Smythies LE et al (2010) Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 298:C1538\u2013C1548. https:\/\/doi.org\/10.1152\/ajpcell.00467.2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.atherosclerosis.2015.06.018","volume":"241","author":"MA Rosenbaum","year":"2015","unstructured":"Rosenbaum MA, Chaudhuri P, Abelson B, Cross BN, Graham LM (2015) Apolipoprotein A-I mimetic peptide reverses impaired arterial healing after injury by reducing oxidative stress. Atherosclerosis 241:709\u2013715. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.06.018","journal-title":"Atherosclerosis"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0022-2275(20)38529-1","volume":"29","author":"GM Anantharamaiah","year":"1988","unstructured":"Anantharamaiah GM et al (1988) Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 29:309\u2013318","journal-title":"J Lipid Res"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.chemphyslip.2019.01.009","volume":"219","author":"CR White","year":"2019","unstructured":"White CR, Datta G, Wilson L, Palgunachari MN, Anantharamaiah GM (2019) The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage. Chem Phys Lipids 219:28\u201335. https:\/\/doi.org\/10.1016\/j.chemphyslip.2019.01.009","journal-title":"Chem Phys Lipids"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/01.ATV.0000167412.98221.1a","volume":"25","author":"M Navab","year":"2005","unstructured":"Navab M et al (2005) D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1426\u20131432. https:\/\/doi.org\/10.1161\/01.ATV.0000167412.98221.1a","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.5551\/jat.33720","volume":"23","author":"M Ikenaga","year":"2016","unstructured":"Ikenaga M, Higaki Y, Saku K, Uehara Y (2016) High-density lipoprotein mimetics: a therapeutic tool for atherosclerotic diseases. J Atheroscler Thromb 23:385\u2013394. https:\/\/doi.org\/10.5551\/jat.33720","journal-title":"J Atheroscler Thromb"},{"key":"11_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000048","volume":"2","author":"Y Uehara","year":"2013","unstructured":"Uehara Y et al (2013) FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J Am Heart Assoc 2:e000048. https:\/\/doi.org\/10.1161\/JAHA.113.000048","journal-title":"J Am Heart Assoc"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4330\/wjc.v6.i10.1049","volume":"6","author":"Y Uehara","year":"2014","unstructured":"Uehara Y, Saku K (2014) High-density lipoprotein and atherosclerosis: roles of lipid transporters. World J Cardiol 6:1049\u20131059. https:\/\/doi.org\/10.4330\/wjc.v6.i10.1049","journal-title":"World J Cardiol"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2015.05.012","volume":"192","author":"T Shimizu","year":"2015","unstructured":"Shimizu T et al (2015) Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo. Int J Cardiol 192:82\u201388. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.012","journal-title":"Int J Cardiol"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1253\/circj.cj-12-0736","volume":"77","author":"E Kawachi","year":"2013","unstructured":"Kawachi E et al (2013) Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. Circ J 77:1482\u20131489. https:\/\/doi.org\/10.1253\/circj.cj-12-0736","journal-title":"Circ J"},{"key":"11_CR45","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","volume":"10","author":"R Kuai","year":"2016","unstructured":"Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A (2016) High-density lipoproteins: Nature's multifunctional nanoparticles. ACS Nano 10:3015\u20133041. https:\/\/doi.org\/10.1021\/acsnano.5b07522","journal-title":"ACS Nano"},{"key":"11_CR46","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1124\/jpet.107.129411","volume":"324","author":"M Gomaraschi","year":"2008","unstructured":"Gomaraschi M et al (2008) Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 324:776\u2013783. https:\/\/doi.org\/10.1124\/jpet.107.129411","journal-title":"J Pharmacol Exp Ther"},{"key":"11_CR47","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/smll.200701285","volume":"4","author":"DP Cormode","year":"2008","unstructured":"Cormode DP et al (2008) An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4:1437\u20131444. https:\/\/doi.org\/10.1002\/smll.200701285","journal-title":"Small"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1194\/jlr.M020438","volume":"53","author":"SC Lu","year":"2012","unstructured":"Lu SC et al (2012) An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice. J Lipid Res 53:643\u2013652. https:\/\/doi.org\/10.1194\/jlr.M020438","journal-title":"J Lipid Res"},{"key":"11_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068802","volume":"8","author":"M Ditiatkovski","year":"2013","unstructured":"Ditiatkovski M et al (2013) An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One 8:e68802. https:\/\/doi.org\/10.1371\/journal.pone.0068802","journal-title":"PLoS One"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"32273","DOI":"10.1074\/jbc.M804461200","volume":"283","author":"AA Sethi","year":"2008","unstructured":"Sethi AA et al (2008) Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 283:32273\u201332282. https:\/\/doi.org\/10.1074\/jbc.M804461200","journal-title":"J Biol Chem"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1194\/jlr.M200475-JLR200","volume":"44","author":"AT Remaley","year":"2003","unstructured":"Remaley AT et al (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44:828\u2013836. https:\/\/doi.org\/10.1194\/jlr.M200475-JLR200","journal-title":"J Lipid Res"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/ATVBAHA.109.200196","volume":"30","author":"F Tabet","year":"2010","unstructured":"Tabet F et al (2010) The 5A apolipoprotein a-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 30:246\u2013252. https:\/\/doi.org\/10.1161\/ATVBAHA.109.200196","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR53","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4049\/jimmunol.1001534","volume":"186","author":"X Yao","year":"2011","unstructured":"Yao X et al (2011) 5A, an apolipoprotein a-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 186:576\u2013583. https:\/\/doi.org\/10.4049\/jimmunol.1001534","journal-title":"J Immunol"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1248\/bpb.b19-00114","volume":"42","author":"H Kawahara","year":"2019","unstructured":"Kawahara H et al (2019) A photo-Activatable peptide mimicking functions of apolipoprotein A-I. Biol Pharm Bull 42:1019\u20131024. https:\/\/doi.org\/10.1248\/bpb.b19-00114","journal-title":"Biol Pharm Bull"},{"key":"11_CR55","doi-asserted-by":"publisher","unstructured":"Gou S et al (2020) A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE(\u2212\/\u2212) mice. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.15213","DOI":"10.1111\/bph.15213"},{"issue":"15","key":"11_CR56","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.3390\/molecules24152829","volume":"24","author":"K Kornmueller","year":"2019","unstructured":"Kornmueller K, Vidakovic I, Prassl R (2019) Artificial high density lipoprotein nanoparticles in cardiovascular research. Molecules 24(15):2829. https:\/\/doi.org\/10.3390\/molecules24152829","journal-title":"Molecules"},{"key":"11_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-019-06865-1","volume":"33","author":"AC Sposito","year":"2019","unstructured":"Sposito AC et al (2019) HDL-targeted therapies during myocardial infarction. Cardiovasc Drugs Ther 33:371\u2013381. https:\/\/doi.org\/10.1007\/s10557-019-06865-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biomaterials.2018.04.011","volume":"170","author":"YJ Sei","year":"2018","unstructured":"Sei YJ et al (2018) Detecting the functional complexities between high-density lipoprotein mimetics. Biomaterials 170:58\u201369. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.04.011","journal-title":"Biomaterials"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.bbamem.2009.06.015","volume":"1788","author":"RF Epand","year":"2009","unstructured":"Epand RF, Mishra VK, Palgunachari MN, Anantharamaiah GM, Epand RM (2009) Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids. Biochim Biophys Acta 1788:1967\u20131975. https:\/\/doi.org\/10.1016\/j.bbamem.2009.06.015","journal-title":"Biochim Biophys Acta"},{"key":"11_CR60","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41598-018-20965-2","volume":"8","author":"RM Islam","year":"2018","unstructured":"Islam RM et al (2018) Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux. Sci Rep 8:2956. https:\/\/doi.org\/10.1038\/s41598-018-20965-2","journal-title":"Sci Rep"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cts.12487","volume":"10","author":"RL Dunbar","year":"2017","unstructured":"Dunbar RL et al (2017) Oral apolipoprotein A-I mimetic D-4F lowers HDL-inflammatory index in high-risk patients: a first-in-human multiple-dose, randomized controlled trial. Clin Transl Sci 10:455\u2013469. https:\/\/doi.org\/10.1111\/cts.12487","journal-title":"Clin Transl Sci"},{"key":"11_CR62","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1194\/jlr.M800539-JLR200","volume":"50","author":"M Navab","year":"2009","unstructured":"Navab M et al (2009) A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 50:1538\u20131547. https:\/\/doi.org\/10.1194\/jlr.M800539-JLR200","journal-title":"J Lipid Res"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.M033555","volume":"54","author":"A Chattopadhyay","year":"2013","unstructured":"Chattopadhyay A et al (2013) A novel approach to oral apoA-I mimetic therapy. J Lipid Res 54:995\u20131010. https:\/\/doi.org\/10.1194\/jlr.M033555","journal-title":"J Lipid Res"},{"key":"11_CR64","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1194\/jlr.M042051","volume":"54","author":"M Navab","year":"2013","unstructured":"Navab M et al (2013) Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res 54:3403\u20133418. https:\/\/doi.org\/10.1194\/jlr.M042051","journal-title":"J Lipid Res"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1194\/jlr.M076554","volume":"58","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee P et al (2017) Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-beta and cholesterol 25-hydroxylase in jejunum. J Lipid Res 58:1636\u20131647. https:\/\/doi.org\/10.1194\/jlr.M076554","journal-title":"J Lipid Res"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MOL.0000000000000615","volume":"30","author":"EK Valanti","year":"2019","unstructured":"Valanti EK, Chroni A, Sanoudou D (2019) The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease. Curr Opin Lipidol 30:326\u2013341. https:\/\/doi.org\/10.1097\/MOL.0000000000000615","journal-title":"Curr Opin Lipidol"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/MOL.0000000000000216","volume":"26","author":"CR White","year":"2015","unstructured":"White CR, Goldberg DI, Anantharamaiah GM (2015) Recent developments in modulating atherogenic lipoproteins. Curr Opin Lipidol 26:369\u2013375. https:\/\/doi.org\/10.1097\/MOL.0000000000000216","journal-title":"Curr Opin Lipidol"},{"key":"11_CR68","first-page":"3482","volume":"8","author":"Y Xu","year":"2016","unstructured":"Xu Y et al (2016) A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. Am J Transl Res 8:3482\u20133492","journal-title":"Am J Transl Res"},{"key":"11_CR69","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1194\/jlr.M085985","volume":"59","author":"GM Anantharamaiah","year":"2018","unstructured":"Anantharamaiah GM et al (2018) Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. J Lipid Res 59:2075\u20132083. https:\/\/doi.org\/10.1194\/jlr.M085985","journal-title":"J Lipid Res"},{"key":"11_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/bi991209w","volume":"39","author":"G Datta","year":"2000","unstructured":"Datta G et al (2000) The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 39:213\u2013220. https:\/\/doi.org\/10.1021\/bi991209w","journal-title":"Biochemistry"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0022-2275(20)31620-5","volume":"42","author":"G Datta","year":"2001","unstructured":"Datta G et al (2001) Cationic domain 141-150 of apoE covalently linked to a class a amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 42:959\u2013966","journal-title":"J Lipid Res"},{"key":"11_CR72","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0021-9150(03)00101-1","volume":"168","author":"DW Garber","year":"2003","unstructured":"Garber DW et al (2003) Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 168:229\u2013237. https:\/\/doi.org\/10.1016\/s0021-9150(03)00101-1","journal-title":"Atherosclerosis"},{"key":"11_CR73","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1161\/CIRCULATIONAHA.104.497107","volume":"111","author":"H Gupta","year":"2005","unstructured":"Gupta H et al (2005) Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation 111:3112\u20133118. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.497107","journal-title":"Circulation"},{"key":"11_CR74","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1194\/jlr.M003665","volume":"51","author":"JK Bielicki","year":"2010","unstructured":"Bielicki JK et al (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496\u20131503. https:\/\/doi.org\/10.1194\/jlr.M003665","journal-title":"J Lipid Res"},{"key":"11_CR75","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbalip.2014.07.018","volume":"1842","author":"A Hafiane","year":"2014","unstructured":"Hafiane A, Bielicki JK, Johansson JO, Genest J (2014) Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochim Biophys Acta 1842:1498\u20131512. https:\/\/doi.org\/10.1016\/j.bbalip.2014.07.018","journal-title":"Biochim Biophys Acta"},{"key":"11_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131997","volume":"10","author":"A Hafiane","year":"2015","unstructured":"Hafiane A, Bielicki JK, Johansson JO, Genest J (2015) Novel Apo E-derived ABCA1 agonist peptide (CS-6253) promotes reverse cholesterol transport and induces formation of prebeta-1 HDL in vitro. PLoS One 10:e0131997. https:\/\/doi.org\/10.1371\/journal.pone.0131997","journal-title":"PLoS One"},{"key":"11_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2018.09.011","volume":"480","author":"S Azhar","year":"2019","unstructured":"Azhar S et al (2019) Novel ABCA1 peptide agonists with antidiabetic action. Mol Cell Endocrinol 480:1\u201311. https:\/\/doi.org\/10.1016\/j.mce.2018.09.011","journal-title":"Mol Cell Endocrinol"},{"key":"11_CR78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/MOL.0000000000000258","volume":"27","author":"JK Bielicki","year":"2016","unstructured":"Bielicki JK (2016) ABCA1 agonist peptides for the treatment of disease. Curr Opin Lipidol 27:40\u201346. https:\/\/doi.org\/10.1097\/MOL.0000000000000258","journal-title":"Curr Opin Lipidol"},{"key":"11_CR79","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.bbamem.2010.10.011","volume":"498-507","author":"VK Mishra","year":"1808","unstructured":"Mishra VK et al (1808) Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G(*) apolipoprotein J peptide using solution NMR. Biochim Biophys Acta 498-507:2011. https:\/\/doi.org\/10.1016\/j.bbamem.2010.10.011","journal-title":"Biochim Biophys Acta"},{"key":"11_CR80","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/jpet.115.229740","volume":"356","author":"T Sakurai","year":"2016","unstructured":"Sakurai T et al (2016) Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther 356:341\u2013353. https:\/\/doi.org\/10.1124\/jpet.115.229740","journal-title":"J Pharmacol Exp Ther"},{"key":"11_CR81","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1124\/jpet.114.220418","volume":"352","author":"MJ Amar","year":"2015","unstructured":"Amar MJ et al (2015) A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther 352:227\u2013235. https:\/\/doi.org\/10.1124\/jpet.114.220418","journal-title":"J Pharmacol Exp Ther"},{"key":"11_CR82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MOL.0000000000000667","volume":"31","author":"P Zanoni","year":"2020","unstructured":"Zanoni P, von Eckardstein A (2020) Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development. Curr Opin Lipidol 31:62\u201370. https:\/\/doi.org\/10.1097\/MOL.0000000000000667","journal-title":"Curr Opin Lipidol"},{"issue":"19","key":"11_CR83","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.3390\/ijms20194807","volume":"20","author":"F Su","year":"2019","unstructured":"Su F et al (2019) A novel HDL-mimetic peptide HM-10\/10 protects RPE and photoreceptors in murine models of retinal degeneration. Int J Mol Sci 20(19):4807. https:\/\/doi.org\/10.3390\/ijms20194807","journal-title":"Int J Mol Sci"},{"key":"11_CR84","doi-asserted-by":"publisher","unstructured":"Su F et al (2020) Bovine HDL and dual domain HDL-mimetic peptides inhibit tumor development in mice. J Cancer Res Ther Oncol 8. https:\/\/doi.org\/10.17303\/jcrto.2020.8.101","DOI":"10.17303\/jcrto.2020.8.101"},{"key":"11_CR85","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","volume":"49","author":"SJ Peterson","year":"2008","unstructured":"Peterson SJ et al (2008) L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 49:1658\u20131669. https:\/\/doi.org\/10.1194\/jlr.M800046-JLR200","journal-title":"J Lipid Res"},{"key":"11_CR86","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1582-4934.2010.01045.x","volume":"15","author":"X Ruan","year":"2011","unstructured":"Ruan X et al (2011) Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med 15:763\u2013772. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01045.x","journal-title":"J Cell Mol Med"},{"key":"11_CR87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MED.0000000000000045","volume":"21","author":"GS Getz","year":"2014","unstructured":"Getz GS, Reardon CA (2014) The structure\/function of apoprotein A-I mimetic peptides: an update. Curr Opin Endocrinol Diabetes Obes 21:129\u2013133. https:\/\/doi.org\/10.1097\/MED.0000000000000045","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"11_CR88","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fphar.2016.00323","volume":"7","author":"EM Gordon","year":"2016","unstructured":"Gordon EM, Figueroa DM, Barochia AV, Yao X, Levine SJ (2016) High-density lipoproteins and apolipoprotein A-I: potential new players in the prevention and treatment of lung disease. Front Pharmacol 7:323. https:\/\/doi.org\/10.3389\/fphar.2016.00323","journal-title":"Front Pharmacol"},{"key":"11_CR89","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.chest.2016.05.035","volume":"150","author":"X Yao","year":"2016","unstructured":"Yao X, Gordon EM, Barochia AV, Remaley AT, Levine SJ (2016) The A\u2019s have it: developing apolipoprotein A-I mimetic peptides into a novel treatment for asthma. Chest 150:283\u2013288. https:\/\/doi.org\/10.1016\/j.chest.2016.05.035","journal-title":"Chest"}],"container-title":["Advances in Experimental Medicine and Biology","HDL Metabolism and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-19-1592-5_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:04:16Z","timestamp":1652663056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-19-1592-5_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9789811915918","9789811915925"],"references-count":89,"URL":"https:\/\/doi.org\/10.1007\/978-981-19-1592-5_11","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s12595-026-00609-4","asserted-by":"object"}]},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"17 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}